These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34917497)

  • 21. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
    Chan SWS; Smith E; Aggarwal R; Balaratnam K; Chen R; Hueniken K; Fazelzad R; Weiss J; Jiang S; Shepherd FA; Bradbury PA; Sacher AG; Leighl NB; Xu W; Brown MC; Eng L; Liu G
    Clin Lung Cancer; 2021 Sep; 22(5):390-407. PubMed ID: 33582072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study.
    Li S; Yang Z; Du H; Zhang W; Che G; Liu L
    ANZ J Surg; 2019 Nov; 89(11):E507-E513. PubMed ID: 31667974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Jiang C; Zhang S; Qiao K; Xiu Y; Yu X; Huang Y
    Clin Breast Cancer; 2022 Jul; 22(5):424-438. PubMed ID: 35428593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Immune-Inflammatory Index Association with Survival in Patients Undergoing Trimodality Therapy for Lung Cancer.
    Coutu BG; Johnson KC; Bhirud A; Baine MJ; Zhen W; Zhang C; Trujillo KP; Bennion NR
    Oncology; 2022; 100(5):247-256. PubMed ID: 34794142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study.
    Shang X; Li Z; Lin J; Wang H; Wang Z
    Cancer Manag Res; 2018; 10():3561-3567. PubMed ID: 30271204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy.
    Fan R; Chen Y; Xu G; Pan W; Lv Y; Zhang Z
    Front Oncol; 2023; 13():996312. PubMed ID: 37077828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.
    Xu S; Cao S; Yu Y
    J Cancer Res Ther; 2021 Dec; 17(7):1636-1642. PubMed ID: 35381733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinogen-to-albumin ratio (FAR) is the best biomarker for the overall survival of patients with non-small-cell lung cancer.
    Ma S; Wang L
    Front Oncol; 2024; 14():1396843. PubMed ID: 38978733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
    Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
    BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection.
    Shen YJ; Qian LQ; Ding ZP; Luo QQ; Zhao H; Xia WY; Fu YY; Feng W; Zhang Q; Yu W; Cai XW; Fu XL
    Front Oncol; 2021; 11():711206. PubMed ID: 34540678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mediastinal radiotherapy after adjuvant chemotherapy for resected non-small cell lung cancer with N2 lymphadenopathy: A novel meta-analysis.
    Harling L; Jayakumar S; Ashrafian H; Bille A; Toufektzian L; Smith D
    JTCVS Open; 2021 Mar; 5():121-130. PubMed ID: 36003173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
    J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
    Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
    Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Minami S; Ihara S; Nishimatsu K; Komuta K
    World J Oncol; 2019 Dec; 10(6):187-198. PubMed ID: 31921375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive effect of the systemic inflammation response index (SIRI) on the efficacy and prognosis of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Ding Y; Liu Z; Li J; Niu W; Li C; Yu B
    BMC Surg; 2024 Mar; 24(1):89. PubMed ID: 38481180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI.
    Phan TT; Ho TT; Nguyen HT; Nguyen HT; Tran TB; Nguyen ST
    Int J Gen Med; 2018; 11():423-430. PubMed ID: 30510441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Postoperative Radiotherapy Effect on Survival of Resected Stage III-N2 Non-small Cell Lung Cancer Patients.
    Gao F; Li N; Xu Y; Yang G
    Front Oncol; 2020; 10():1135. PubMed ID: 32850322
    [No Abstract]   [Full Text] [Related]  

  • 40. Predictive value of pre-operative prognostic nutritional index and systemic immune-inflammation index for efficacy and survival in patients with non-small cell lung cancer undergoing neoadjuvant chemotherapy.
    Lan J; Lin W; Lai Y; Zhang J
    Am J Transl Res; 2024; 16(5):2024-2033. PubMed ID: 38883356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.